Posted by Michael Wonder on 17 Jun 2020
Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
17 June 2020 - FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis, which is part of the axial spondyloarthritis disease spectrum.
Novartis today announced that the US FDA has approved Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis, confirming Cosentyx efficacy in addressing the axial spondyloarthritis disease spectrum.
